Neose receives milestone payment from Novo Nordisk for second of three proteins

By Angela McDaniels

Seattle, Nov. 21 - Neose Technologies Inc. said it has received a milestone payment from Novo Nordisk AS under its 2003 license agreements to use Neose's GlycoPEGylation technology to develop next-generation versions of three currently marketed therapeutic proteins.

This is the second of three proteins for which Neose has received a milestone payment.

"We are pleased not only with the progress this milestone payment represents, but with the overall success of our three-protein collaboration with Novo Nordisk," Neose chief executive officer and chairman C. Boyd Clarke said in a company news release.

Novo Nordisk is a Copenhagen-based health care company that manufactures and markets pharmaceutical products for haemostasis management, growth hormone therapy, hormone replacement therapy and for the treatment of diabetes.

Neose is a Horsham, Pa.-based biopharmaceutical company using its enzymatic technologies to develop improved drugs; primarily therapeutic proteins.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.